Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA

< Previous 1 2 Next >
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
From VALNEVA
Via GlobeNewswire
Valneva Hosts Investor Day in New York City
From VALNEVA
Via GlobeNewswire
Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
From VALNEVA
Via GlobeNewswire
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
From VALNEVA
Via GlobeNewswire
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
From VALNEVA
Via GlobeNewswire
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
From VALNEVA
Via GlobeNewswire
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
From VALNEVA
Via GlobeNewswire
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
From VALNEVA
Via GlobeNewswire
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
From VALNEVA
Via GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
From VALNEVA
Via GlobeNewswire
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
From VALNEVA
Via GlobeNewswire
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
From VALNEVA
Via GlobeNewswire
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
From VALNEVA
Via GlobeNewswire
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
From VALNEVA
Via GlobeNewswire
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
From VALNEVA
Via GlobeNewswire
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
From VALNEVA
Via GlobeNewswire
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
From VALNEVA
Via GlobeNewswire
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
From VALNEVA
Via GlobeNewswire
Valneva Announces Sale of Priority Review Voucher for $103 Million
From VALNEVA
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.